Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study.
In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.
D000328:Adult; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D010919:Placebos; D014745:Viloxazine / Q000009:adverse effects / Q000627:therapeutic use*
D009025:Morpholines; D010919:Placebos; D014745:Viloxazine; D007099:Imipramine